Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Nanobiotix ( (NBTX) ) just unveiled an update.
On May 20, 2026, Nanobiotix announced the launch of an approximately €75 million global follow-on equity offering of American Depositary Shares, ordinary shares and pre-funded warrants, with the size potentially increased depending on investor demand. The transaction, led by Jefferies, TD Cowen and Stifel, will be priced via an immediate book-building process, with U.S. ADS pricing mirroring the euro-denominated price in the international tranche and subject to a possible 15% discount to the recent Euronext volume-weighted average price.
The capital increase will be carried out without preferential subscription rights for existing shareholders under prior shareholder authorizations, and includes a 30-day option for underwriters to purchase up to 15% additional ADSs. Net proceeds are earmarked primarily to advance Nanobiotix’s Nanoprimer and other platforms, with a smaller portion directed to development of JNJ-1900 (NBTXR3) and general corporate purposes, while management and board members, as well as the company, are bound by a 90-day lock-up, underscoring a commitment to capital structure stability during this financing.
The most recent analyst rating on (NBTX) stock is a Buy with a $36.00 price target. To see the full list of analyst forecasts on Nanobiotix stock, see the NBTX Stock Forecast page.
Spark’s Take on NBTX Stock
According to Spark, TipRanks’ AI Analyst, NBTX is a Neutral.
The score is primarily constrained by weak financial fundamentals (ongoing losses, cash burn, and balance-sheet pressure including negative equity and higher leverage). Offsetting this are strong technical momentum (though extended) and a constructive earnings-call outlook emphasizing improved runway and multiple clinical catalysts, while valuation support is limited given negative earnings and no dividend.
To see Spark’s full report on NBTX stock, click here.
More about Nanobiotix
Nanobiotix S.A. is a late-clinical stage biotechnology company based in Paris and Cambridge, Mass., specializing in physics-based approaches to expand treatment options for cancer and other major diseases. Its lead programs include JNJ-1900 (NBTXR3), and it is listed on both the Nasdaq Global Select Market in the U.S. and Euronext Paris, targeting global oncology markets.
Average Trading Volume: 76,716
Technical Sentiment Signal: Buy
Current Market Cap: $2.08B
Learn more about NBTX stock on TipRanks’ Stock Analysis page.